Latest Asx Companies News

Ryder Capital has reported a remarkable 227% increase in comprehensive income for the half-year ending December 2025, alongside a record net tangible asset growth and a new quarterly dividend policy.

Actinogen Medical has locked in a $4.3 million tranche of non-dilutive funding to support its pivotal Alzheimer’s disease trial, reinforcing its financial position as it nears critical interim and final results.

Imricor Medical Systems has achieved a major milestone with FDA clearance for its Vision-MR Diagnostic Catheter, paving the way for commercial sales in the US electrophysiology market.

Auris Minerals Limited has been queried by the ASX following a sharp rise in its share price and trading volume, with the company denying any undisclosed information behind the surge.

Tissue Repair Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, denying any undisclosed information and confirming compliance with listing rules.

Chimeric Therapeutics has won FDA Orphan Drug Designation for its CHM CDH17 CAR-T therapy targeting gastric cancer, advancing its clinical development with regulatory incentives and potential market exclusivity.

Activeport Group Ltd has revised the timetable for its pro-rata bonus issue of unquoted options, outlining key dates and eligible shareholders across multiple countries.

Singular Health has submitted a 510(k) premarket notification to the FDA for its enhanced 3DICOM MD Cloud platform, aiming to expand imaging capabilities and introduce a scalable, cloud-native solution for medical image management.

Sagalio Energy Limited’s shares have been suspended from ASX trading due to compliance concerns, leaving investors in the dark about the company’s next steps.

Vectus Biosystems has responded to an ASX price query following a dramatic spike in its share price and trading volume, denying any undisclosed information and confirming compliance with ASX rules.

Anteris Technologies has updated the timetable for its Australian capital raising, delaying settlement to November 4 and the start of trading for new securities to November 5. The company also highlights restrictions on U.S. investors acquiring its CDIs.

InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.